Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference

 Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company
                            Health Care Conference

PR Newswire

RICHMOND, Calif., Feb. 27, 2013

RICHMOND, Calif., Feb. 27, 2013 /PRNewswire/ --Sangamo BioSciences, Inc.
(Nasdaq: SGMO) announced today that Geoff Nichol, M.B., Ch.B., Sangamo's
executive vice president, research and development, will provide an update on
the progress of Sangamo's ZFP Therapeutic^® development programs and an
overview of the company's business strategy at 10:40 am ET on Wednesday, March
6, 2013, at the 33^rd Annual Cowen and Company Health Care Conference which
will be held in Boston.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The presentation will be webcast live and may be accessed via a link on the
Sangamo BioSciences website in the Investor Relations section under Events and
Presentations. The presentation will be archived on the Sangamo website for
two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel
DNA-binding proteins for therapeutic gene regulation and genome editing. The
Company has ongoing Phase 2 clinical trials to evaluate the safety and
efficacy of a novel ZFP Therapeutic^® for the treatment of HIV/AIDS. Sangamo's
other therapeutic programs are focused on monogenic diseases, including
hemophilia, Huntington's disease and hemoglobinopathies such as
beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable
the engineering of a class of DNA-binding proteins known as zinc finger
DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific
DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs)
for gene modification and ZFP transcription factors (ZFP TFs) that can control
gene expression and, consequently, cell function. Sangamo has entered into a
strategic collaboration with Shire AG to develop therapeutics for hemophilia,
Huntington's disease and other monogenic diseases and has established
strategic partnerships with companies in non-therapeutic applications of its
technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more
information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic^® is a registered trademark of Sangamo BioSciences, Inc.

SOURCE Sangamo BioSciences, Inc.

Website: http://www.sangamo.com
Contact: Elizabeth Wolffe, Ph.D, +1-510-970-6000, x271, ewolffe@sangamo.com